Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDG-PET/CT early response assessment during neoadjuvant chemotherapy for esophageal and esophagogastric junction adenocarcinoma
2011-001856-12Phase 4Completed
- Sponsor
- Motol University Hospital
- Start
- Jul 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cisplatin, epirubicin, fluorouracil and capecitabine in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma, sponsored by Motol University Hospital. Primary endpoint: Threshold decrease in FDG-PET/CT metabolic parameters at day 14. Started Jul 2011; status: completed.
02
Drugs
cisplatinepirubicinfluorouracilcapecitabine
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2011-001856-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001856-12.